1443239-80-2

Upstream product

• 317806-87-4 2,2,2-trichloroethyl 3-tert-butyl-1-p-tolyl-1H-pyrazol-5-ylcarbamate 
• 1443242-57-6 2,2,2-trifluoro-N-[(S)‐4‐carbonyl-1,2,3,4-tetrahydronaphthalen-1-yl]acetamide 
• 23357-52-0 (S)-1,2,3,4-tetrahydronapht-1-yl-amine 
• 1351997-20-0 (1R,4S)-aminoN-(S)-4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-ol 
• 1443242-59-8 2,2,2-trifluoro-N-((1S,4R)-4-hydroxy-1,2,3,4-tetrahydro-naphthalen-1-yl)-acetamide 
• 1443243-18-2 [5-((1R,4S)-4-amino-1,2,3,4-tetrahydro-naphthalen-1-yloxy)-pyridin-2-yl]-morpholin-4-yl-methanone 
• 1443243-17-1 (5-fluoro-pyridin-2-yl)-morpholin-4-yl-methanone 
• 327056-62-2 5-fluoropicolinonitrile 

Downstream Products

• 1443239-85-7 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(6-morpholin-4-ylmethyl-pyridin-3-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea 

Relevant academic research and scientific papers

KINASE INHIBITORS

Compounds of formula (I) and pharmaceutically acceptable salts thereof: wherein R2, W, A, Y and R1 are as defined in the specification, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.

KINASE INHIBITORS

Compounds of formula (I) or a pharmaceutically acceptable salt thereof: formula (I) wherein R2, W, A, Y and R1 are as defined in the specification, are p38 MAPK inhibitors, useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.